The MOU is a non-binding exploratory step with no financial commitments or near-term catalyst. Monitor for subsequent regulatory filings (ethics committee approvals, clinical trial registration) which would signal progression. Without concrete milestones or funding details, this event has limited standalone trading significance.
Price Chart
Executive Summary
Alpha Tau Medical signed a non-binding MOU with Samsung Medical Center (SMC) in Seoul, South Korea, to explore a potential clinical trial of its Alpha DaRT alpha-radiation therapy in pancreatic cancer patients. The MOU is exploratory and subject to regulatory and ethics approvals, with no financial terms or definitive timeline disclosed. This is a modest expansion of the company's geographic footprint into Asia but lacks concrete commitments or near-term revenue implications.
Key Facts
- MOU signed with Samsung Medical Center (SMC), ranked #5 globally and #1 in Korea in oncology (Newsweek 2027).
- Potential clinical trial targets pancreatic cancer, Korea's 4th leading cause of cancer death with a 17% 5-year survival rate.
- Any trial is subject to regulatory and ethics committee approvals; no timeline or financial terms disclosed.
- This would be Alpha DaRT's first clinical trial in South Korea, expanding its pancreatic cancer program to potentially six countries.
- Alpha DaRT has marketing approval only in Japan for head and neck cancer; no other commercial approvals exist.
Financial Impact
No financial terms, upfront payments, milestones, or revenue projections disclosed in the MOU.
Risk Factors
- MOU is non-binding and may not lead to a clinical trial or commercial partnership.
- Pancreatic cancer is a notoriously difficult indication with high clinical trial failure rates.
- Alpha Tau has no approved products outside Japan and limited operating history with ongoing losses.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $12.90 | awaiting T+60 | awaiting T+60 | $13.51 (+4.73%) |
Oct 22, 2026 5d ago | Press Release | $12.90 | awaiting T+60 | awaiting T+60 | $13.51 (+4.73%) |
Oct 19, 2026 8d ago | 6-K | $12.62 | awaiting T+60 | awaiting T+60 | $13.51 (+7.05%) |
Oct 19, 2026 8d ago | Press Release | $12.62 | awaiting T+60 | awaiting T+60 | $13.51 (+7.05%) |
Aug 31, 2026 8w ago | 6-K | $14.11 | awaiting T+60 | awaiting T+60 | $13.51 (−4.25%) |
Aug 10, 2026 11w ago | 6-K | $14.27 | awaiting T+60 | awaiting T+60 | $13.51 (−5.33%) |
Aug 10, 2026 11w ago | Press Release | $14.27 | awaiting T+60 | awaiting T+60 | $13.51 (−5.33%) |
Aug 10, 2026 11w ago | 6-K | $13.60 | awaiting T+60 | awaiting T+60 | $13.51 (−0.66%) |
Jul 21, 2026 14w ago | 6-K | $13.32 $13.74 | ▲ +3.15% | ▼ −0.82% | $13.51 (+1.43%) |
Jul 15, 2026 14w ago | 6-K | $12.46 $14.00 | ▲ +12.36% | ▲ +9.83% | $13.51 (+8.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers